How useful would starting exactitude be in an obese 68 year old woman with an elevated lipid panel but no cardiovascular events

For an obese 68-year-old woman with elevated lipids and no prior heart attack or stroke, the evidence for starting a statin is mixed and weaker than most doctors will tell you.

The best trial data for her age group comes from the JUPITER trial, which tested rosuvastatin 20 mg in people over 70 with normal LDL but elevated CRP. In the 5,695 participants older than 70, the drug cut the combined risk of heart attack, stroke, and cardiovascular death by about 39% over roughly two years [3]. That sounds large, but the absolute numbers matter more. In the whole JUPITER trial, treating 10,000 people for two years prevented about 32 heart attacks while causing about 70 cases of muscle pain [14]. The benefit was concentrated in people with high inflammation, not just high cholesterol.

The PROSPER trial tested pravastatin 40 mg in adults aged 70 to 82 and found a clear benefit only in those who already had heart disease. For primary prevention in that age group, the benefit was essentially zero: a hazard ratio of 0.94, meaning no detectable reduction in heart attacks or strokes [3]. The CTT meta-analysis, which pooled 28 trials, found that in people over 75 with no prior vascular disease, statins reduced major vascular events by only 8%, and that result did not reach statistical significance [3].

The Danish diabetes cohort showed that the benefit in primary prevention grows with age: about 4 fewer events per 100 people over 5 years in the 60-69 group, and about 8 per 100 in the 70-79 group [1]. But that study was in people with diabetes, not the general population, and the benefit depended on high adherence.

Obesity matters here. A meta-analysis of 29 trials found that the cardiovascular benefit of intensive LDL-lowering therapy was strongest in people with a BMI under 25 and essentially disappeared in people with a BMI over 30 [26]. For an obese woman, the expected benefit from a statin is smaller than the trial averages suggest.

The risk of new-onset diabetes is real. A meta-analysis of 11 studies found that statin use increased the odds of developing diabetes by about 60 to 90 percent, depending on the analysis [32]. For a 68-year-old woman who is already obese and may have prediabetes, that trade-off matters.

My call: the evidence supports considering a moderate-dose statin if her calculated 10-year risk is above 15% and her CRP is elevated, but the benefit for an obese woman with no prior events is modest at best, and the diabetes risk is not trivial. The evidence does not support a strong recommendation to start. Confidence: moderate.